JP2017210444A - Lipase inhibitor containing urolithin - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a novel lipase inhibitor.SOLUTION: The present invention provides a lipase inhibitor containing urolithin.SELECTED DRAWING: Figure 1

Description

  The present invention relates to a lipase inhibitor containing urolithins.

  Pancreatic lipase is a digestive enzyme synthesized in the pancreas and secreted into the pancreatic juice to hydrolyze triacylglycerol. Fat ingested by meal is absorbed from small intestinal epithelial cells after being decomposed into fatty acid and glycerin by the action of lipase, which is a lipolytic enzyme. It is known that if absorption of such triacylglycerol can be suppressed in the digestion and absorption process, obesity can be improved by suppressing the accumulation of visceral fat. One method of suppressing the absorption of such food-derived fat is a method of suppressing the action of pancreatic lipase. Based on this, powerful lipase inhibitors aimed at reducing visceral fat, weight loss, etc. have been used as obesity treatments mainly in Europe and the United States, but side effects such as diarrhea and abdominal pain have been reported and are not necessarily safe It's hard to say. Since the lipase inhibitory action that can be obtained from foods or food ingredients suppresses digestion and absorption of fat, such foods are promising as highly safe health-oriented foods that are expected to lower blood lipids. Is being viewed.

  So far, kaempferol, apigenin and the like have been investigated as flavonoids as substances exhibiting a lipase activity inhibitory action, and reported to show an inhibitory action (Patent Document 1). Moreover, it is known that the tea-derived extract has a lipid digestion and absorption inhibitory effect, and it has been reported that a tea extract-derived compound, particularly catechins, exhibits a lipase inhibitory action. For example, Patent Document 2 reports that epicatechin gallate (EGCG) inhibits lipase activity. In addition, catechins such as theacinensin and assamicaine, theaflavins (Patent Document 3), procyanidins (Patent Document 4), and polymerized polyphenols derived from oolong tea (Patent Document 5) are derived from a wide range of tea extracts. Compounds have been reported. In addition, there is a report on lipase inhibition in sclerothioline produced by Penicillium sclerotiorum (Patent Document 6).

On the other hand, it is known that a polyphenol called urolithin exists. Urolithins represented by urolithin A are known as ellagic acid metabolites derived from ellagitannins contained in pomegranate, raspberry, blackberry, cloudberry, strawberry, walnut and the like. It is known that ellagitannins are classified into hydrolyzable tannins, and when ingested, they are hydrolyzed and converted to ellagic acid.
Although ellagitannins and ellagic acid are said to have very low intestinal absorption in the body, when they are ingested, they are known to be further metabolized by the human colonic microflora and converted to urolithins. Yes. The urolithins thus produced are one of the most important compounds in the living body. In recent years, Gordonibacter urolithinfaciens has been reported as an intestinal bacterium that produces urolithins (Non-patent Document 1).

Regarding the production of urolithin in the living body, it was reported in a test using rats that urolithin is produced as an in vivo metabolite of ellagitannin by ingesting ellagitannin such as geraniin and then analyzing urine in urine. (Non-Patent Document 2). Non-Patent Document 3 reports that in humans, urolithin analogs are detected in urine after ingestion of pomegranate extract containing ellagitannin mainly punicalagin, and urolithin A functions as a main metabolite. Has been. It has been reported that urolithin A has various efficacy such as antioxidative action (Non-Patent Document 4), anti-inflammatory action (Non-Patent Document 5), anti-glycation action (Non-Patent Document 6), obesity, and metabolism. Treatment or prevention of symptoms selected from the group consisting of reduced speed, metabolic syndrome, diabetes, cardiovascular disease, hyperlipidemia, neurodegenerative disease, cognitive impairment, mood disorder, stress and anxiety disorder, weight management, muscle function or In order to improve mental ability, foods or nutritional supplements containing urolithin A which is one of urolithins have been reported (Patent Document 7). Thus, it is required to add urolithins to foods, raw materials for pharmaceuticals, processed products thereof, and the like. However, lipase inhibitory action involving urolithins is not known.

Japanese Patent Laid-Open No. 7-61927 JP-A-3-228664 International Publication 2006/004114 Pamphlet JP 2006-016367 A JP 2006-001909 A JP 2000-191527 A JP-T-2014-501764

Int. J. Syst. Evol. Microbiol. 64, 2346-2352 (2014) J. Agric. Food Chem. 56 (2), 393-400 (2008) Mol. Nutr. Food Res. 58, 1199-1211 (2014) Biosci. Biotechnol. Biochem. 76 (2), 395-399 (2012) J. Agric. Food Chem. 60 (36), 8866-8876 (2012) Mol. Nutr. Food Res. 55, S35-S43 (2011)

  The present invention has been made under the above circumstances, and an object of the present invention is to provide a novel lipase inhibitor. Another object of the present invention is to provide a fat absorption inhibitor containing the lipase inhibitor as a novel fat absorption inhibitor. It is another object of the present invention to provide a novel lipase-inhibiting food or drink and a novel fat absorption-inhibiting food or drink.

As a result of searching for a novel lipase inhibitor, the present inventors have found that urolithins inhibit the lipase action and completed the present invention. That is, the present invention is as follows.
[1] A lipase inhibitor containing urolithins.
[2] The lipase inhibitor according to [1], wherein the urolithins are one or more selected from the group consisting of urolithin A, urolithin B, urolithin C, urolithin D, and urolithin E.
[3] A fat absorption inhibitor comprising the lipase inhibitor according to [1] or [2].
[4] A lipase-inhibiting food or drink containing urolithins.
[5] A food or drink for fat absorption suppression containing urolithins.

  According to the present invention, a lipase inhibitor containing urolithins can be provided as a novel lipase inhibitor. Moreover, the fat absorption inhibitor containing this lipase inhibitor can be provided as a novel fat absorption inhibitor. Moreover, the lipase inhibition food / beverage products containing urolithins can be provided as a novel lipase inhibition food / beverage product. Furthermore, as a novel fat absorption suppressing food or drink, a fat absorption suppressing food or drink containing urolithins can be provided.

It is a graph which shows the relationship between the urolithin A density | concentration and lipase inhibition rate in one embodiment of this invention. It is a graph which shows the relationship between the urolithin B density | concentration and lipase inhibition rate in one embodiment of this invention. It is a graph which shows the relationship between the urolithin C density | concentration and lipase inhibition rate in one embodiment of this invention. It is a graph which shows the relationship between the urolithin D density | concentration and lipase inhibition rate in one embodiment of this invention. It is a graph which shows the relationship between the urolithin E density | concentration and lipase inhibition rate in one embodiment of this invention.

  The present invention includes a first embodiment relating to a lipase inhibitor containing urolithins and a second embodiment relating to a fat absorption inhibitor containing the lipase inhibitor.

<1. Lipase inhibitors containing urolithins>
The first embodiment of the present invention is a lipase inhibitor containing urolithins represented by the following general formula (1).

(Urolithins)
Although the urolithin in 1st embodiment is not specifically limited, The structure is a substance represented by the said General formula (1). In addition, as shown in Table 1, urolithins are represented by R1-R6 in the chemical formula, and urolithin A, urolithin B, urolithin C, urolithin D, urolithin E, urolithin M3, urolithin M4, urolithin M5, urolithin M6, urolithin M7, and Isouroritin A and the like are included.

  Among these, since lipase inhibitory action is high, urolithin A, urolithin B, urolithin C, urolithin D and urolithin E are preferable, among which urolithin A and urolithin B are more preferable, and urolithin A is more preferable.

The method for obtaining urolithins is not particularly limited, and commercially available products may be used, or they may be synthesized by chemical synthesis.
Examples of commercially available urolithins include urolithin A, urolithin B, urolithin C, urolithin D, urolithin E (Dalton Pharma) and the like.
In addition, as a synthetic method by chemical synthesis, conventional methods can be used. For example, as described in Examples of the present specification, urolithin A using 2-bromo-5-methoxybenzoic acid and aluminum chloride as raw materials. Is a method of synthesizing.

Alternatively, punicalagin, a kind of ellagitannin, may be extracted from plants and hydrolyzed into ellagic acid, or ellagic acid may be extracted and converted to urolithins using microorganisms.
The kind of plant is not particularly limited, and examples include pomegranate, raspberry, blackberry, cloudberry, boysenberry, strawberry, walnut, and ginger. Of these, pomegranate, boysenberry and genokosho are preferred, and pomegranate is more preferred because of its high content of ellagitannin and / or ellagic acid.
Any one of these plants may be used, or two or more thereof may be used in combination. Moreover, the extraction method and extraction conditions from this plant are not specifically limited, What is necessary is just to follow a conventional method. For example, a known extraction method such as water extraction, hot water extraction, hot water extraction, alcohol extraction, supercritical extraction or the like can be used.

When performing solvent extraction, the solvent may be, for example, water; alcohols such as lower alcohols such as methanol and ethanol, and polyhydric alcohols such as propylene glycol and 1,3-butylene glycol (anhydrous or hydrated). ); Ketones such as acetone; esters such as diethyl ether, dioxane, acetonitrile, and ethyl acetate; xylene; and the like, preferably water and ethanol. Any one of these solvents may be used, or two or more thereof may be used in combination.
The method for hydrolyzing the extracted ellagitannin such as punicalagin to ellagic acid is not particularly limited, and examples thereof include a method of hydrolyzing with an acid, an enzyme, and a microorganism.
The method for converting ellagic acid to urolithins using a microorganism is not particularly limited, and for example, a known method described in Food Funct., 5, 8, 1779-1784 (2014) can be used. .

  Although the obtained urolithins can be used as they are, they may be dried and used in a powder form. Moreover, you may refine | purify, a concentration process, etc. to the obtained urolithins as needed. As the purification treatment, treatment such as filtration or adsorption or decolorization using an ion exchange resin or activated carbon column can be performed. As the concentration treatment, a conventional method such as an evaporator can be used.

  In addition, the obtained urolithins (or purified product or concentrate) are subjected to a freeze-drying process, and powdered by spray-drying by adding excipients such as dextrin, corn starch, and gum arabic. You may powder according to well-known methods, such as a method. Further, it may be used after being dissolved in pure water, ethanol or the like as required.

(Lipase inhibitor)
The lipase in this embodiment has, for example, the action of hydrolyzing the ester bond of triacylglycerol and inhibiting the activity of an enzyme having the action of breaking down into fatty acid and glycerin. That is, the lipase in this embodiment is a triacyl Glycerol lipase is preferred.

  The lipase activity can be evaluated according to a known method. Triacylglycerol lipase can be evaluated by, for example, using 4-methylumbelliferone fatty acid ester as a substrate and quantifying 4-methylumbelliferone released after the enzymatic reaction by a fluorescence measurement method.

As described in the background art, fat ingested by diet is broken down into fatty acids and glycerin by the action of lipase and then absorbed from small intestinal epithelial cells. Therefore, inhibiting lipase activity is useful for the prevention and treatment of obesity because it can suppress fat absorption and suppress visceral fat accumulation.
From this, the lipase inhibitor which concerns on this embodiment is used preferably for the use of fat absorption suppression, The preferable form is a pharmaceutical, food-drinks, and a supplement.

  The lipase inhibitor which concerns on this embodiment may contain 1 type among above-described urolithins, and may contain multiple types. In addition, urolithins may be contained alone, but in addition to urolithins, known excipients, fragrances, colorants, emulsifiers, stabilizers, thickeners, enzymes, preservatives, lubricants, surfactants Agents, disintegrants, disintegration inhibitors, binders, absorption accelerators, adsorbents, moisturizers, solubilizers, preservatives, flavoring agents, sweetening agents, etc., as necessary, as long as the effects of the present embodiment are not impaired. Can be blended.

  The content of urolithins relative to the total amount of the lipase inhibitor is not particularly limited as long as the desired effect according to this embodiment is achieved, but the total amount of urolithins is usually 0.00001% by mass or more, preferably 0.0001% by mass. Above, more preferably 0.001% by mass or more, and usually 20% by mass or less, preferably 3% by mass or less, more preferably 1% by mass or less.

(Medicine)
When the lipase inhibitor according to this embodiment is used as a pharmaceutical material, the dosage form can be selected according to the disease to be prevented or treated, the use form of the medicine, the administration route, and the like. Examples include tablets, coated tablets, pills, capsules, granules, powders, solutions, suspensions, emulsions, syrups, injections, suppositories, dip agents, decoction, tinctures and the like. These various preparations are prepared according to conventional methods as necessary with respect to the active ingredient, such as fillers, extenders, excipients, binders, humectants, disintegrants, surfactants, lubricants, coloring agents, flavoring agents. The pharmaceutical composition can be formulated using known adjuvants that can be usually used in the pharmaceutical preparation technical field, such as solubilizing agents, suspension agents, and coating agents. Moreover, you may contain a coloring agent, a preservative, a fragrance | flavor, a flavoring agent, a sweetening agent, etc. and other pharmaceuticals in this pharmaceutical formulation.
Moreover, as a preferable disease, it originates in fat absorption, for example, obesity is mentioned.

  The content of the lipase inhibitor relative to the total amount of the drug is not particularly limited as long as the desired effect according to each invention is exhibited, but the total amount of urolithins is usually 0.0001% by mass or more, preferably 0.001% by mass or more. More preferably, the content is 0.01% by mass or more, and is usually 10% by mass or less, preferably 1% by mass or less, and more preferably 0.1% by mass or less.

(Food)
When the lipase inhibitor according to this embodiment is used as a material for food and drink, in addition to general food and drink, food for specified health use, nutritional supplement, functional food, food for the sick, food additive, etc. Beverages are also included, and are the same herein). As for the form of food and drink, not the plants or animals containing urolithin itself, but soft drinks, milk, pudding, jelly, rice cake, gum, gummy, yogurt, chocolate, soup, cookies, snacks, ice cream, popsicles , Bread, cake, cream puff, ham, meat sauce, curry, stew, cheese, butter, dressing and the like.

  The food / beverage products containing the lipase inhibitor which concerns on this embodiment can use water, protein, saccharide | sugar, a lipid, vitamins, minerals, organic acid, organic base, fruit juice, flavors, etc. as a main component. Examples of the protein include whole milk powder, skim milk powder, partially skim milk powder, casein, soybean protein, chicken egg protein, meat protein, and other animal and vegetable proteins, and their hydrolysates and butter. Examples of the saccharide include saccharides, processed starch (in addition to dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like. Examples of lipids include lard, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, hydrogenated oil, and vegetable oils such as transesterified oil. Examples of vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline. And minerals include, for example, calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, selenium, and whey minerals. Examples of the organic acid include malic acid, citric acid, lactic acid, and tartaric acid. Two or more of these components may be used in combination, or a synthetic product and / or a food or drink containing a large amount thereof may be used.

The food / beverage products containing the lipase inhibitor which concerns on this embodiment can be manufactured in accordance with a conventional method. Moreover, the compounding quantity, the compounding method, and compounding time to the food / beverage products of the lipase inhibitor which concerns on this embodiment can be selected suitably. Furthermore, it can be enclosed in appropriate containers, such as a bottle, a bag, a can, a box, and a pack, as needed.
The content of the lipase inhibitor relative to the total amount of food and drink is not particularly limited as long as the desired effect according to each invention is exhibited, but the total amount of urolithins is usually 0.0001% by mass or more, preferably 0.001% by mass. Above, more preferably 0.01% by mass or more, and usually 10% by mass or less, preferably 1% by mass or less, more preferably 0.1% by mass or less.

(supplement)
A supplement is one of the food and drink categories consisting of dietary supplements, and in this specification refers to a functional auxiliary substance that exhibits a lipase inhibitory action and the like.
When using the lipase inhibitor which concerns on this embodiment as a raw material of a supplement, it can be set as any form of a solid substance, a gel-like substance, and a liquid substance. Examples of supplements include various processed foods and drinks, powders, tablets, pills, capsules, jellies, granules, and the like.

  When the lipase inhibitor according to this embodiment is used as a supplement material, excipients such as dextrin, preservatives such as vitamin C, flavoring agents such as vanillin, pigments such as safflower pigments, monosaccharides, oligosaccharides and polysaccharides It may contain additives such as saccharides (eg, glucose, fructose, sucrose, saccharose, and saccharides containing these), acidulants, fragrances, fats and oils, emulsifiers, whole milk powder, or agar. These components may be used in combination of two or more, and may contain many synthetic products and / or these.

  When using the lipase inhibitor which concerns on this embodiment as a raw material of a supplement, it can manufacture according to a conventional method. Moreover, the compounding quantity to a supplement, a compounding method, and a compounding time can be selected suitably. Furthermore, it can be enclosed in appropriate containers, such as a bottle, a bag, a can, a box, and a pack, as needed.

  The content of the lipase inhibitor relative to the total amount of the supplement is not particularly limited as long as the above effect is exhibited, but as a urolithin, the total amount is usually 0.0001% by mass or more, preferably 0.001% by mass or more, more preferably. Is 0.01% by mass or more, and is usually 10% by mass or less, preferably 1% by mass or less, more preferably 0.1% by mass or less.

(display)
Medicines, foods and drinks, supplements and the like containing the lipase inhibitor according to this embodiment may be sold as drugs, foods and drinks, supplements, etc. with a label indicating that they are used for lipase inhibitory action. it can.

  The “display” means all acts for informing the consumer of the use, and if it is a display that can recall and analogize the use, the purpose of the display, the content of the display, the display Regardless of the object, medium, etc. to be performed, all correspond to “display” in each embodiment. However, it is preferable to display in such an expression that the consumer can directly recognize the application. Specifically, an act that describes the above-mentioned use in a product or product packaging related to medicine, food and drink, supplements, etc., a product or product packaging that describes the above-mentioned use is transferred, and is delivered, transferred or delivered Exhibiting and importing, displaying advertisements related to products, price lists or transaction documents for display or distribution, or describing the above uses in information containing these contents (such as the Internet) ) The act provided by the method can be exemplified.

  On the other hand, the display is preferably a display approved by the government or the like (for example, a display which is approved based on various systems determined by the government and is performed in a mode based on such approval). Display on advertising materials at sales sites such as catalogs, pamphlets, and POPs, and other documents is preferable.

In addition, for example, if it is a food or drink containing the lipase inhibitor according to this embodiment, health foods, functional foods, special-purpose foods, nutritional functional foods (these include beverages. The same applies in this specification. ), An indication as a quasi-drug, etc., and other indications approved by the Ministry of Health, Labor and Welfare, for example, foods for specified health use and indications approved under a similar system. Examples of the latter can include a display as a food for specified health use, a display as a condition specific food for specified health use, a display that affects the structure and function of the body, a display for reducing disease risk, etc. Speaking of the health promotion law enforcement regulations (April 30, 2003 Ministry of Health, Labor and Welfare Ordinance No. 86) labeling as food for specified health use (especially labeling the use of health), and similar The display can be listed as a typical example.

<2. Fat absorption inhibitor>
The second embodiment of the present invention is a fat absorption inhibitor containing the lipase inhibitor according to the first embodiment.
The fat absorption inhibitor according to this embodiment may contain the lipase inhibitor according to the first embodiment alone, but in addition to the above components, known excipients, fragrances, colorants, emulsifiers, stabilization Agent, thickener, enzyme, preservative, lubricant, surfactant, disintegrant, disintegration inhibitor, binder, absorption enhancer, adsorbent, moisturizer, solubilizer, preservative, flavoring agent, sweetness An agent etc. can be mix | blended as needed in the range which does not impair the effect of this embodiment.

  The content of the lipase inhibitor according to the first embodiment relative to the total amount of the fat absorption inhibitor is not particularly limited as long as the desired effect according to this embodiment is exhibited, but is usually 0.0001% by mass as the total amount of urolithins. As mentioned above, Preferably it is 0.001 mass% or more, More preferably, it is 0.01 mass% or more, and is 10 mass% or less normally, Preferably it is 1 mass% or less, More preferably, it is 0.1 mass% or less.

  The fat absorption inhibitor according to this embodiment can be used in the form of medicine, food and drink, supplements, and the like according to the embodiment. The description described in the first embodiment is used for the description of the fat absorption inhibitor according to this embodiment.

  In addition, the fat absorption inhibitory action which concerns on this embodiment originates in urolithins. Therefore, as another embodiment of the present invention, “a fat absorption inhibitor containing urolithins” can be mentioned. The description described in the first embodiment and the second embodiment is used for the description of the fat absorption inhibitor containing urolithins.

  Hereinafter, the present invention will be described in more detail with reference to specific examples, but the present invention is not limited to these examples.

(Method for analyzing urolithins)
A case where urolithin A is used as an example of urolithins will be described. Analysis of urolithin A was performed using HPLC. That is, a solution prepared by dissolving urolithin A (Dalton Pharma) in an appropriate solvent was analyzed under the following HPLC conditions, and the purity (%) (A) and the peak area value (B) in HPLC were used. The urolithin A factor and the urolithin A concentration of the sample were calculated by the following calculation formula (1) and calculation formula (2).

(Calculation factor of urolithin A factor)
Factor of urolithin A = (B) / (concentration of standard solution of urolithin A (mg / L) × (A) / 100) (1)
(Sample urolithin A concentration calculation formula)
Sample urolithin A concentration (mg / L) = peak area value of urolithin A in the sample / factor of urolithin A (2)

(Analysis conditions)
Analytical column: Inertsil ODS-3 (250 × 4.6 mm) (manufactured by GL Science)
Detection wavelength: 305 nm
Mobile phase: water / acetonitrile / acetic acid = 74/25/1
Column temperature: 40 ° C
Flow rate: 1.0 mL / min
Under the above conditions, urolithin A had a retention time of 16.5 minutes.

(Preparation of urolithin A)
2-Bromo-5-methoxybenzoic acid 5 g (manufactured by Wako Pure Chemical Industries, Ltd.) and aluminum chloride 15 g were refluxed in 150 mL of chlorobenzene for 2.5 hours. After cooling, the reaction solution was transferred to ice water and extracted three times with 250 mL of diethyl ether. The obtained extract was concentrated under reduced pressure, and diethyl ether was distilled off to obtain 4.2 g of 2-bromo-5-hydroxybenzoic acid. 3.9 g of the obtained 2-bromo-5-hydroxybenzoic acid and 3.9 g of resorcinol (manufactured by Tokyo Chemical Industry Co., Ltd.) were heated in 9 mL of 4M NaOH aqueous solution at 60 ° C. for 30 minutes. After adding 1.8 mL of 10% aqueous copper sulfate solution to the reaction solution, heating was further performed at 80 ° C. for 10 minutes. The produced precipitate was collected by filtration to obtain a white powder of urolithin A.

<Evaluation of lipase inhibition>
[Example 1]
After 2.0 mg of porcine pancreatic lipase (manufactured by Sigma) was dissolved in 10 mL of 100 mM McIlvaine buffer (pH 7.4), the mixture was centrifuged (3000 rpm, 10 minutes), and the supernatant was recovered to prepare an enzyme solution. In a 96-well microplate, 25 μL of 0.05 mM 4-methylumbelliferyl heptanoic acid (manufactured by Funakoshi) and final concentrations of urolithin A of 7.81 mg / L, 15.6 mg / L, 31.3 mg / L, 62 100 μL of a test sample solution was added so as to be 5 mg / L or 125 mg / L, and preincubation was performed at 37 ° C. for 10 minutes. Thereafter, 25 μL of the enzyme solution was added, and an enzyme reaction was performed at 37 ° C. for 30 minutes in a total amount of 150 μL of the reaction solution. The reaction was stopped by adding 20 μL of a 100 mM sodium carbonate solution, and the fluorescence intensity of 4-methylumbelliferone produced by the enzyme reaction was measured under the conditions of an excitation wavelength of 340 nm and a fluorescence wavelength of 420 nm. When the lipase inhibitory activity is large, the fluorescence intensity of 4-methylumbelliferone is small.

[Comparative Example 1]
A control (Comparative Example 1) was used in the same manner as in Example 1 except that urolithin A was not added.

  In addition, a blank was used as in Example 1 except that neither the enzyme solution nor urolithin A was added.

The lipase inhibition rate was calculated by the following calculation formula (3).
Lipase inhibition rate (%) = {(CB) / (CA)} × 100 (3)
A: Fluorescence intensity of blank (no enzyme added, test sample added) B: Fluorescent intensity of test reaction solution (Example 1) (enzyme added, test sample added) C: Control (Comparative Example 1) (enzyme added, test) Fluorescence intensity without sample)

  A graph showing the relationship between the urolithin A concentration and the lipase inhibition rate is shown in FIG. As shown in FIG. 1, an increase in the lipase inhibition rate was observed depending on the concentration of urolithin A, and it was confirmed that urolithin A acts as a lipase inhibitor.

[Example 2, Comparative Example 2]
The same procedure as in Example 1 was performed except that a reaction solution was prepared using commercially available urolithin B (manufactured by Dalton Pharma) as a test sample.

  A graph showing the relationship between the urolithin B concentration and the lipase inhibition rate is shown in FIG. As shown in FIG. 2, an increase in the lipase inhibition rate was observed depending on the concentration of urolithin B, and it was confirmed that urolithin B acts as a lipase inhibitor.

[Example 3, Comparative Example 3]
Using commercially available urolithin C (Dalton Pharma) as a test sample, reaction was performed so that the final concentration was 15.6 mg / L, 31.3 mg / L, 62.5 mg / L, 125 mg / L, or 250 mg / L. The same procedure as in Example 1 was performed except that the solution was prepared.

  A graph showing the relationship between the urolithin C concentration and the lipase inhibition rate is shown in FIG. As shown in FIG. 3, an increase in the lipase inhibition rate was observed depending on the concentration of urolithin C, and it was confirmed that urolithin C acts as a lipase inhibitor.

[Example 4, Comparative Example 4]
The same procedure as in Example 3 was performed except that a reaction solution was prepared using commercially available urolithin D (Dalton Pharma) as a test sample.

  A graph showing the relationship between the urolithin D concentration and the lipase inhibition rate is shown in FIG. As shown in FIG. 4, an increase in the lipase inhibition rate was observed depending on the concentration of urolithin D, and it was confirmed that urolithin D acts as a lipase inhibitor.

[Example 5, Comparative Example 5]
Using commercially available urolithin E (Dalton Pharma) as a test sample, the reaction solution was adjusted so that the final concentration was 31.3 mg / L, 62.5 mg / L, 125 mg / L, 250 mg / L, or 500 mg / L. The same procedure as in Example 1 was performed except for the preparation.

  A graph showing the relationship between the urolithin E concentration and the lipase inhibition rate is shown in FIG. As shown in FIG. 5, an increase in the lipase inhibition rate was observed depending on the concentration of urolithin E, and it was confirmed that urolithin E acts as a lipase inhibitor.

  The present invention can be applied to pharmaceutical techniques such as pharmaceuticals, foods and drinks, and supplements. These are used for lipase inhibition, fat absorption suppression and the like.

Claims (5)

  A lipase inhibitor containing urolithins.   The lipase inhibitor according to claim 1, wherein the urolithin is one or more selected from the group consisting of urolithin A, urolithin B, urolithin C, urolithin D, and urolithin E.   The fat absorption inhibitor containing the lipase inhibitor of Claim 1 or 2.   A lipase-inhibiting food or drink containing urolithins.   A food and drink for suppressing fat absorption containing urolithins.

Images